Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

721 recalls, newest first

Class II · Moderate risk

Sucralfate Tablets

CGMP Deviations: The recalling firm filed for Chapter 11 in September 2024. As a result, it cannot monitor the quality program and hence cannot assure that products meet the identity, strength, quality, and purity characteristics that they are purported or represented to possess, rendering the products adulterated.

Ongoing cGMP deviation Amerisource Health Services LLC NDC 60687-695-01 D-0598-2025
Class II · Moderate risk

Doxepin Hydrochloride Capsules

CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.

Ongoing Nitrosamine impurity Alembic Pharmaceuticals Limited NDC 62332-637-31 D-0566-2025
Class III · Low risk

Albuterol Sulfate

Failed Stability Specifications: Out of specification results was observed in Induction Port during the analysis of Particle size distribution at the 12-month time point.

Ongoing Stability / shelf life Cipla USA, Inc. NDC 69097-142-60 D-0593-2025
Class II · Moderate risk

Lorazepam Injection

Failed Impurities/Degradation Specifications: An out-of-Specification for total related compounds

Ongoing Impurity / degradation Hikma Pharmaceuticals USA Inc. NDC 0641-6044-25 D-0551-2025
Class II · Moderate risk

Belsomra (suvorexant)

Failed Dissolution Specifications: potential for delayed dissolution of the dose after administration which may result in delayed release of the drug, delaying onset of sleep.

Ongoing Dissolution failure Merck & Co. Inc NDC 0006-0033-10 D-0584-2025

Recalls by year